


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DGT NO.
4-30188/CGC 1955/R
APPLICATION NO.
09/139,254
APPLICANT
FUJIMOTO ET AL.
FILING DATE
AUGUST 25, 1998



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Sircar J.C., Curr.Opin.Invest.Drugs, Vol. 2 (4), pp. 403-407 (1993)
AS	Englehardt G., Z. Rheumatol, Vol. 53, Suppl. 1, pg. 68 (1994)
AT	Englehardt G., Eur. J., Clin. Pharmacology, Vol. 47 (No. 1) pg. A98 (1994)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188/CGC-1955/R
APPLICATION NO.
09/139,254
APPLICANT
FUJIMOTO ET AL.
FILING DATE
AUGUST 25, 1998



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Brit. J. Pharmacol., Vol. 112, Proc. Suppl., pg. 183P (1994)
AB	Klein T. et al., Biochemical Pharmacology, Vol. 48, No. 8, pp 1605-1610 (1994)
AC	Mitchell J.A. et al., Proc.Natl.Acad.Sci.USA, Vol. 90, pp. 11693-11697 (1994)
AD	Pallapies D. et al., Life Sciences, Vol. 57, No. 2, pp. 83-89 (1995)
AE	Pairet M. et al., Proceedings of a conference, October 10-11, 1995, "Improved Non-Steroid Anti-Inflammatory Drugs COX-2 Enzyme Inhibitors", Edited by John Vane et al., pp. 103-119
AF	Seibert K. et al., Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Vol. 23, pg. 125-127 (1995)
AG	Englehardt G., Br.J.Rheumatol. Vol. 34, Abstr. Suppl. 1, pg. 48 (1995)
AH	Glaser K.B., Inflammopharmacology, Vol. 3, pp. 335-345, (1995)
AI	Gierse J.K. et al., Biochem.J., Vol. 305, pp. 479-484 (1995)
AJ	Prasit P. et al., Med.Chem.Res., Vol. 5, pp. 364-374 (1995)
AK	Chan Chi-Chung et al., Journ.Pharmacology and Experimental Therapeutics, Vol. 274, pp. 1531-1537 (1995)
AL	Grossman C.J. et al., Inflammation Res., Vol. 44, pp. 253-257 (1995)
AM	Glaser K.B. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S276 (1995)
AN	

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188/CGC 1955/R
APPLICATION NO.
09/139,254
APPLICANT
FUJIMOTO ET AL.
FILING DATE
AUGUST 25, 1998



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Grossman C.J. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S272 (1995)
AB	Warner T.D. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S274 (1995)
AC	Terlain B. et al., Presse Med., Vol. 24, No. 10, pp. 491-496 (1995)
AD	Gierse J.K. et al., Journ.Biological Chemistry, Vol. 271, No. 26, pp. 15810-15814 (1996)
AE	Englehardt G., Z. Rheumatol. Vol. 55, Suppl. 1, pg. 112 (1996)
AF	Distel M. et al., British Jour. of Rheumatology, Vol. 35 (suppl. 1) pp. 68-77 (1996)
AG	Churchill L. et al., Inflammopharmacology, Vol. 4, pp. 125-135 (1996)
AH	Steinilber D., Pharm.Ztg., Vol. 141(37), pp. 11-18 (1996)
AI	Vane J.R. et al., Scan.J.Rheumatol. Vol. 25 (Suppl. 102) pp. 9-21 (1996)
AJ	Matsushita M. et al., Inflamm.Res., Vol. 46, pp. 461-466 (1997)
AK	Englehardt G. et al., Biochemical Pharmacology, Vol. 51, pp. 21-28 (1996)
AL	Cromlish W.A. et al., Biochemical Pharmacology, Vol. 52, pp. 1777-1785 (1996)
AM	Brideau C. et al., Inflamm.Res., Vol. 45, pp. 68-74 (1996)
AN	

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. [REDACTED]
4-30188/CGC 19/5/R
APPLICATION NO. 09/139,254
APPLICANT FUJIMOTO ET AL.
FILING DATE AUGUST 25, 1998



Group
1613

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Patrignani P. et al., Journal of Physiology and Pharmacology, Vol. 48, 4, pp. 623-631 (1997)
AB	Pairet M. et al., Proceedings of a conference on March 20-21, 1997, "Selective COX-2 Inhibitors Pharmacology, Clinical Effects and Therapeutic Potential" Edited by John Vane et al., pp. 27-46
AC	Dammann H.G. et al., Clinical Pharmacology & Therapeutics, Vol. 61, pg. 162 (1997)
AD	Pairet M. et al., Infamm. Res., Vol. 47, Suppl. 2, pp. S93-S101 (1998)
AE	Silvestre J. et al., Drugs of the Future, Vol. 23(6), pp. 598-601 (1998)
AF	Giuliano F. et al., Brit. J.Pharmacol., Vol. 125, Suppl. 1, 35P (1998)
AG	Simmons D.L. et al., Journal of Lipid Mediators, Vol. 6, pp. 113-117 (1993)
AH	Japanese Pharmacol. Ther., Vol. 25, No. 8, pp. 2131-2136 (1997)
AI	Japanese Journal of Inflammation, Vol. 15, No. 5, pp. 409-411 (1995)
AJ	Cryer B. et al., Amer.J.Med., Vol. 104, No. 5, pp. 413-421 (1998)
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.